Key facts
- AvantGuard (Specialty Chemicals)’s last known valuation is $5.7M (May 2021).
- It has raised $4.4M; the latest was Seed Round in Feb 2026.
- Notable investors include Plug and Play Tech Center, US National Science Foundation, SOSV, United States Department of War, National Institutes of Health — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for AvantGuard (Specialty Chemicals)
- ·The full record, as it builds
Funding rounds
No funding rounds for AvantGuard (Specialty Chemicals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AvantGuard (Specialty Chemicals)
Manufacturer of antiseptic/topical treatments intended to treat infections and fight fungi, bacteria, and their biofilms on skin and in wounds. The company's products can also be used in a wide variety of applications depending on concentration; at a higher concentration sterilizes medical devices but is still safe enough for skin contact; at a lower concentration is an oral antiseptic; still lower makes water safe to drink.
- Sector
- Materials and Resources
- HQ
- New York, NY, United States
- Founded
- 2018
- Employees
- 18
- Website
- avantguardinc.com/
- Ownership
- Privately Held (backing)
AvantGuard (Specialty Chemicals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AvantGuard (Specialty Chemicals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AvantGuard (Specialty Chemicals) in its N-PORT filings yet. We sweep new filings monthly.